• OUR RESEARCH
    • NASH
    • Targets & Clinical Progress
    • Posters/Publications
  • OUR PIPELINE
    • Pipeline
    • Clinical Trials
    • Expanded Access Policy
  • OUR STORY
    • Overview
    • Management Team
    • Partnership
  • NEWS
  • CAREERS

OUR RESEARCH

  • NASH
  • Targets & Clinical Progress
  • Posters/Publications

OUR PIPELINE

  • Pipeline
  • Clinical Trials
  • Expanded Access Policy

OUR STORY

  • Overview
  • Management Team
  • Partnership

NEWS

CAREERS

News

  • 2021
  • 2020
  • 2019
  • First Subject Dosed with Gannex’s FXR Agonist ASC42 in a U.S. Phase I Trial

    28/12/2020

  • Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial

    22/12/2020

  • Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42,an FXR Agonist

    14/12/2020

  • Gannex Appoints Former Takeda Head of Liver Disease Clinical Development Melissa Palmer, MD as Chief Medical Officer

    30/11/2020

  • ASC40 (TVB-2640) Phase 2 NASH Trial Completed Patient Enrollment in China

    19/11/2020

  • Gannex Received U.S. IND Approval for Its NASH Drug Candidate ASC42,an FXR Agonist

    12/10/2020

  • Ascletis’ Strategic Partner Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640(ASC40) in NASH at AASLD’s The Liver Meeting Digital Experience™ 2020

    10/10/2020

  • Gannex Filed US IND for Its NASH Drug ASC42, an FXR Agonist

    14/09/2020

  • Gannex and Galmed Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)

    09/09/2020

  • Bridging Study in China Completed for NASH Drug Candidate ASC40

    20/07/2020

FIND US:

All contents © Copyright Gannex Pharma Co., Ltd.All Rights Reserved

This site is published by Gannex Pharma Co., Ltd.

which is solely responsible for all site content.